overweight or obese polycystic ovary syndrome
Conditions
Interventions
Group A:Dydrogesterone
Group B:Drospirenone and Ethinylestradiol Tablets (II)
Sponsors
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Signed and dated informed consent; 2. Chinese, female of reproductive age between 16 and 40 years old; 3. Overweight patients with 28kg/m2 > BMI >= 24kg/m2 and WC >= 80cm; 4. PCOS was diagnosed according to Guidelines formulated by the Chinese Medical Association in 2018: (1) Rare ovulation or anovulation: clinical manifestations are amenorrhea, oligomenorrhea, menarche 2-3 years can not establish regular menstruation and basic body temperature is uniphase. Sometimes menstruation is regular but no ovulation; (2) Clinical manifestations of hyperandrogen and hyperandrogenemia: clinical manifestations include acne and hypertrichosis; (3) Ovarian polycystic changes: B ultrasound examination showed that the diameter of one or both sides of the ovary 2-9 mm follicles >= 12 and/or ovarian volume >= 10cm3. Two of the above three conditions were consistent, and other diseases causing high androgen, such as congenital adrenal cortical hyperplasia, Cushing syndrome and androgen-secreting tumors, will be excluded. PCOS can be diagnosed. 5. Application of Dydrogesterone Tablets or Drospirenone and Ethinylestradiol Tablets (II) treatment.
Exclusion criteria
Exclusion criteria: 1. Drug contraindication; 2. Smokers or former smokers; 3. Abnormal uterine bleeding outside PCOS, such as endometriosis, adenomyosis or unexplained abnormal uterine bleeding; 4. Pregnancy or breastfeeding; 5. Have a family history of thrombosis; 6. People with high risk of venous or arterial thrombosis, patients with multiple risk factors or with higher severity of individual risk factors should consider the possibility of a synergistic increase in thrombosis risk. This increased risk may be greater than the simple cumulative risk factor; 7. Alcohol, drug abuse or drug exposure period; 8. Suffering from serious genetic, physical or mental diseases; 9. Hormone drugs or ovulation induction therapy were used in the first 3 months; 10. Participated in other clinical research in the past 3 months; 11. Suffer from reproductively transmitted diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TC;TG; | — |
Secondary
| Measure | Time frame |
|---|---|
| body weight;WHR;LDL-C;HDL-C;FSH;LH;E2;T;P;FT;TT;PRL;AMH;SHGB;FPG;liver function test;Renal function test;B-mode ultrasonography of vagina;Bleeding pattern;FPG;FINS; | — |
Countries
China
Contacts
Public ContactXiangyan Ruan
Beijing Obstetrics & Gynecology Hospital, Capital Medical university
Outcome results
None listed